When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Wegovy diet plan: What foods to eat and avoid while taking ...

   www.aol.com/wegovy-diet-plan-foods-eat-160000849...

   High-sodium foods, including salty snacks like chips, canned soups, cold cuts, and fast food, can contribute to water retention and interfere with efficient digestion. Wegovy in and of itself can ...

3. 8 Reasons You May Still Be Hungry on Semaglutide - AOL

   www.aol.com/8-reasons-may-still-hungry-115800064...

   Hunger Won’t Disappear on Semaglutide. First up, hunger is a normal bodily sensation, and semaglutide won’t make it stop altogether. The type 2 diabetes and weight loss drug can suppress your ...

4. Protein-sparing modified fast (diet) - Wikipedia

   en.wikipedia.org/wiki/Protein-sparing_modified...

   The concept of "protein-sparing modified fast" (PSMF) was described by George Blackburn in the early 1970s as an intensive weight-loss diet designed to mitigate the harms associated with protein-calorie malnutrition [8] and nitrogen losses induced by either acute illness or hypocaloric diets in patients with obesity, in order to adapt the patient's metabolism sufficiently to use endogenous fat ...

5. 15 Alternatives to Ozempic for Weight Loss - AOL

   www.aol.com/15-alternatives-ozempic-weight-loss...

   Ozempic is an FDA-approved medication for people who have type 2 diabetes. It’s often prescribed “off-label” for weight loss — when a drug is prescribed for something it’s not approved for.

6. Very-low-calorie diet - Wikipedia

   en.wikipedia.org/wiki/Very-low-calorie_diet

   VLCD were not found to increase food cravings, and on the contrary, appear to reduce food cravings more than low-calorie diets. [ 29 ] Previous formulations (medical or commercial) of carbohydrate-free very low calorie diets provided 200–800 kcal/day and maintained protein intake, but eliminated any carbohydrate intake and sometimes fat ...

7. GLP-1 receptor agonist - Wikipedia

   en.wikipedia.org/wiki/GLP-1_receptor_agonist

   The 2022 American Diabetes Association standards of medical care recommend GLP-1 agonists as a first-line therapy for type 2 diabetes, specifically in patients with atherosclerotic cardiovascular disease or obesity. The drugs were also noted to reduce food intake and body weight significantly, and some have been approved to treat obesity in the ...